Levosalbutamol
| Evidence Level: L5 | Predicted Indications: 9 |
Table of Contents
Levosalbutamol: Nasal cavity disease
One-Sentence Summary
Levosalbutamol is a selective beta-2 adrenergic agonist bronchodilator. The TxGNN model predicts it may be relevant to nasal cavity disease, but this is a model prediction only: the data compiled for this report contain no clinical trials and no publications for this disease.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Nasal cavity disease |
| TxGNN Prediction Score | 0.9999 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Levosalbutamol is known as a selective beta-2 adrenergic agonist, the class that relaxes airway smooth muscle.
For the nasal cavity, a link is only speculative. Beta-2 agonism might affect mucosal blood vessels and produce a decongestant-like effect, but no study in the compiled data tests this. The high score therefore reflects a pattern found by the model, not demonstrated benefit. It should be treated as a hypothesis for early exploration only.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
Levosalbutamol is marketed in India. All 20 licences in the compiled data are valid and are single-ingredient products. The list may be partial. Approved-indication text is not recorded for these licences. Five main authorisations:
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 121411 | Levolin Synchrobreathe Inhaler (Cipla Ltd) | Box of 120 MDI inhaler | Not listed |
| 120835 | Levolin 50mcg Inhaler (Cipla Ltd) | Packet of 200 MDI inhaler | Not listed |
| 199887 | Salbair 50mcg Transhaler (Lupin Ltd) | Packet of 250 MDI Transhaler | Not listed |
| 151733 | Nebulair Respules 2ml (Dr Reddy’s Laboratories Ltd) | Strip of 7 respules | Not listed |
| 224595 | Tiecuf L Syrup (Indica Biolife Sciences) | Bottle of 100 ml syrup | Not listed |
Safety Considerations
- Drug Interactions: 146 interactions were found in the interaction database. Moderate-level examples include epinephrine, ephedrine, isometheptene, famotidine, clarithromycin, phentermine, diethylpropion, cisapride, dolasetron, palonosetron and inhaled insulin. Minor-level examples are corticosteroids such as hydrocortisone, dexamethasone, budesonide, betamethasone, triamcinolone and beclomethasone.
Package insert warnings and contraindications are not available in the compiled data; please refer to the package insert for them.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is very high (0.9999), but it is not backed by any trial or publication on nasal cavity disease, and the mechanistic link is speculative. The evidence level is L5.
To proceed, the following is needed:
- Mechanism of action data and a plausible biological rationale for nasal effects
- Preclinical or early clinical studies addressing nasal cavity disease directly
- Package insert warnings and contraindications from the Indian regulator
- Assessment of route and formulation suitability for nasal use
Review Log
Below is the review log for this page: statements checked against official Indian medicine data (the Indian Medicine Dataset used by this site). Corrections are limited to basic factual statements; model predictions, evidence levels, and conclusions were not rewritten.
| Review date | Item | Action | Source |
|---|---|---|---|
| 2026-10-31 | Removed: “Its only registered trial was withdrawn with no participants, so no completed Phase 3 trial confirms it” | No longer present after the report was regenerated (2026-11-12: the report was regenerated in 2026-11 and no longer contains this statement; was: Corrected) | Indian Medicine Dataset |
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.